Clarity Pharmaceuticals Secures Copper-64 Supply Agreement with Nusano

Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) just unveiled an announcement.

Clarity Pharmaceuticals has entered into a commercial-scale supply agreement with Nusano for copper-64 isotopes, which will bolster its existing network of suppliers in the US. This agreement is a strategic move to ensure a reliable and abundant supply of isotopes, supporting Clarity’s late-stage clinical trials and upcoming commercialization efforts. The partnership with Nusano, which is set to begin production in 2025, positions Clarity to overcome current market limitations and enhance its competitive edge in the oncology diagnostics market, particularly with its SAR-bisPSMA product for prostate cancer diagnosis.

More about Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on developing and commercializing next-generation products to improve cancer treatment outcomes. The company is a leader in innovative radiopharmaceuticals, particularly in the development of Targeted Copper Theranostics using its SAR Technology Platform.

YTD Price Performance: -56.12%

Average Trading Volume: 2,159,279

Technical Sentiment Signal: Buy

Current Market Cap: A$560.8M

See more data about CU6 stock on TipRanks’ Stock Analysis page.